Leerink Partners Upgrades Compass Therapeutics (NASDAQ:CMPX) to Outperform

Leerink Partners upgraded shares of Compass Therapeutics (NASDAQ:CMPX - Free Report) from a market perform rating to an outperform rating in a report issued on Wednesday morning, Marketbeat Ratings reports. The brokerage currently has $6.00 price target on the stock, up from their prior price target of $4.00.

CMPX has been the subject of a number of other research reports. Guggenheim began coverage on shares of Compass Therapeutics in a research note on Monday, February 24th. They issued a "buy" rating and a $12.00 price objective for the company. Jefferies Financial Group upped their target price on Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a report on Monday, February 10th. Wedbush reissued an "outperform" rating and set a $8.00 target price on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Piper Sandler began coverage on Compass Therapeutics in a report on Wednesday, February 19th. They set an "overweight" rating and a $12.00 price objective for the company. Finally, D. Boral Capital restated a "buy" rating and issued a $32.00 target price on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $13.38.

Remove Ads

Compass Therapeutics Stock Performance

Shares of CMPX stock traded up $0.08 during mid-day trading on Wednesday, hitting $1.54. 694,789 shares of the stock traded hands, compared to its average volume of 817,678. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $4.08. The company's 50-day simple moving average is $2.76 and its 200-day simple moving average is $2.11. The firm has a market cap of $212.82 million, a price-to-earnings ratio of -4.15 and a beta of 1.40.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). Analysts forecast that Compass Therapeutics will post -0.36 earnings per share for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Squarepoint Ops LLC acquired a new stake in shares of Compass Therapeutics during the 4th quarter worth approximately $35,000. Tang Capital Management LLC raised its stake in Compass Therapeutics by 225.4% during the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock worth $8,555,000 after acquiring an additional 4,087,005 shares in the last quarter. ProShare Advisors LLC lifted its holdings in Compass Therapeutics by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock valued at $42,000 after purchasing an additional 9,451 shares during the last quarter. MPM Bioimpact LLC grew its stake in Compass Therapeutics by 51.9% during the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock worth $12,423,000 after buying an additional 2,926,002 shares during the last quarter. Finally, Enavate Sciences GP LLC acquired a new position in shares of Compass Therapeutics in the 4th quarter worth approximately $11,293,000. Institutional investors and hedge funds own 68.43% of the company's stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.